1. O’Callaghan, J. P. & Miller, D. B. Neurotoxic effects of substituted amphetamines in rats and mice. in Handbook of Neurotoxicology (ed. Massaro, E.J.) 269–301 (Human Press NJ., Totowa, 2005).

2. Jimenez, A. et al. Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol Appl Pharmacol 196:223–234 (2004).

3. Schmidt, C. J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1–7 (1987).

4. Stone, D. M., Stahl, D. C., Hanson, G. R. & Gibb, J. W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41–48 (1986).

5. Darvesh, A. S. & Gudelsky, G. A. Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res 1056:168–175 (2005).

6. Dluzen, D. E. et al. Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity. Curr Neuropharmacol 9:40–44 (2011).

7. Fredholm, B. B. et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143–156 (1994).

8. Ribeiro, J. A., Sebastiao, A. M. & de Mendonca, A. Participation of adenosine receptors in neuroprotection. Drug News Perspect 16:80–86 (2003).

9. Fredholm, B. B., AP, I. J., Jacobson, K. A., Klotz, K. N. & Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552 (2001).

10. Fontinha, B.M. et al. Adenosine A (2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. Neuropsychopharmacology 34:1865–1874 (2009).

11. Ruiz-Medina, J., Ledent, C., Carreton, O. & Valverde, O. The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA. J Psychopharmacol 25:550–564 (2011).

12. Kaplan, G. B. & Sears, M. T. Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (Berl) 123:64–70 (1996).

13. Salem, A. & Hope, W. Effect of adenosine receptor agonists and antagonists on the expression of opiate withdrawal in rats. Pharmacol Biochem Behav 57:671–679 (1997).

14. Calfee-Mason, K. G., Lee, E. Y., Spear, B. T. & Glauert, H. P. Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate. Food Chem Toxicol 46:2062–2073 (2008).

15. Pennypacker, K. R., Kassed, C. A., Eidizadeh, S. & O’Callaghan, J. P. Brain injury: prolonged induction of transcription factors. Acta Neurobiol Exp (Wars) 60: 515–530 (2000).

16. Yamamoto, Y. & Gaynor, R. B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 29:72–79 (2004).

17. Tiangco, D. A. et al. 3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells. Cardiovasc Toxicol 5:301–310 (2005).

18. Kaltschmidt, C., Kaltschmidt, B. & Baeuerle, P. A. Brain synapses contain inducible forms of the transcription factor NF-kappa B. Mech Dev 43:135–147 (1993).

19. Kaltschmidt, C., Kaltschmidt, B., Neumann, H., Wekerle, H. & Baeuerle, P. A. Constitutive NF-kappa B activity in neurons. Mol Cell Biol 14, 3981-3992 (1994).

20. Galter, D., Mihm, S. & Droge, W. Distinct effects of glutathione disulphide on the nuclear transcription factor kappa B and the activator protein-1. Eur J Biochem 221:639–648 (1994).

21. Kelly, K. A., Miller, D. B., Bowyer, J. F. & O’Callaghan, J. P. Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. J Neurochem 122:995–1009 (2012).

22. Kuhn, D. M., Francescutti-Verbeem, D. M. & Thomas, D. M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci 1074:31–41 (2006).

23. Ladenheim, B. et al. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 58:1247–1256 (2000).

24. Montiel-Duarte, C., Ansorena, E., Lopez-Zabalza, M. J., Cenarruzabeitia, E. & Iraburu, M. J. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine (“Ecstasy”) on hepatic stellate cells. Biochem Pharmacol 67:1025–1033 (2004).

25. Tiangco, D. A., Halcomb, S., Lattanzio, F. A., Jr. & Hargrave, B. Y. 3,4-Methylenedioxymethamphetamine alters left ventricular function and activates nuclear factor-kappa B (NF-kappaB) in a time and dose dependent manner. Int J Mol Sci 11:4843–4863 (2010).

26. Kermanian, F. et al. The role of adenosine receptor agonist and antagonist on Hippocampal MDMA detrimental effects; a structural and behavioral study. Metab Brain Dis 27:459–469 (2012).

27. Kermanian, F., Soleimani, M., Ebrahimzadeh, A., Haghir, H. & Mehdizadeh, M. Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-κB expression preceded by MDMA toxicity. Metab Brain Dis 28:45–52 (2013).

28. Bexis, S. & Docherty, J. R. Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Br J Pharmacol 147:926–934 (2006).

29. McNamara, R., Maginn, M. & Harkin, A. Caffeine induces a profound and persistent tachycardia in response to MDMA (“Ecstasy”) administration. Eur J Pharmacol 555:194–198 (2007).

30. Vandeputte, C. & Docherty, J. R. Vascular actions of 3,4-methylenedioxymethamphetamine in alpha (2A/D)-adrenoceptor knockout mice. Eur J Pharmacol 457:45–49 (2002).

31. Schreck, R., Albermann, K. & Baeuerle, P. A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 17:221–237 (1992).

32. Arrigo, A. P. Gene expression and the thiol redox state. Free Radic Biol Med 27:936–944 (1999).

33. Bouloumie, A., Schini-Kerth, V. B. & Busse, R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41:773–780 (1999).

34. Bowie, A. G. & O’Neill, L. A. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 165:7180–7188 (2000).

35. Colado, M. I. et al. A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827–833 (1997).

36. Imam, S. Z. et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci 939:366–380 (2001).

37. Shankaran, M., Yamamoto, B. K. & Gudelsky, G. A. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 385:103–110 (1999).

38. Miranda, M. et al. Oxidative stress in rat retina and hippocampus after chronic MDMA (’ecstasy’) administration. Neurochem Res 32:1156–1162 (2007).

39. Broening, H. W., Morford, L. L., Inman-Wood, S. L., Fukumura, M. & Vorhees, C. V. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228–3235 (2001).

40. Vorhees, C. V. et al. (+/−)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty. Dev Neurosci 31:107–120 (2009).

41. Baumann, M. H., Wang, X. & Rothman, R. B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407–424 (2007).

42. Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E. & Colado, M. I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55:463–508 (2003).

43. Kramer, K., Azmitia, E. C. & Whitaker-Azmitia, P. M. In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse. Brain Res Dev Brain Res 78:142–146 (1994).

44. Badon, L. A. et al. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther 302:898–907 (2002).

45. Garcia, G. E. et al. Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J 22:445–454 (2008).

46. Pedata, F., Corsi, C., Melani, A., Bordoni, F. & Latini, S. Adenosine extracellular brain concentrations and role of A2A receptors in ischemia. Ann N Y Acad Sci 939:74–84 (2001).

47. Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920 (2001).

48. Sullivan, G. W., Fang, G., Linden, J. & Scheld, W. M. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 189:1897–1904 (2004).

49. Boison, D. & Shen, H. Y. Adenosine Kinase is a new therapeutic targetto prevent ischemic neuronal death. Open Drug Dis J 2:108–118 (2010).

50. Latini, S., Pazzagli, M., Pepeu, G. & Pedata, F. A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen Pharmacol 27:925–933 (1996).

51. Barger, S. W. & Mattson, M. P. Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer’s beta-amyloid precursor. Brain Res Mol Brain Res 40:116–126 (1996).

52. Guo, Q., Robinson, N. & Mattson, M. P. Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis. J Biol Chem 273:12341–12351 (1998).

53. Kaltschmidt, C., Kaltschmidt, B. & Baeuerle, P. A. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc Natl Acad Sci U S A 92:9618–9622 (1995).

54. Lezoualc’h, F., Sagara, Y., Holsboer, F. & Behl, C. High constitutive NF-kappaB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 18:3224–3232 (1998).

55. Hatano, E. et al. NF-kappaB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis. Gastroenterology 120:1251–1262 (2001).

56. Liu, H., Lo, C. R. & Czaja, M. J. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35:772–778 (2002).

57. Blondeau, N., Widmann, C., Lazdunski, M. & Heurteaux, C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 21:4668–4677 (2001).

58. Ravati, A., Ahlemeyer, B., Becker, A., Klumpp, S. & Krieglstein, J. Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappaB. J Neurochem 78:909–919 (2001).

59. Hasko, G. & Pacher, P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83:447–455 (2008).

60. Milne, G. R. & Palmer, T. M. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. Scientific World Journal 11:320–339 (2011).

61. Arolfo, M. P., Yao, L., Gordon, A. S., Diamond, I. & Janak, P. H. Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. Alcohol Clin Exp Res 28:1308–1316 (2004).

62. Bachtell, R. K. & Self, D. W. Effects of adenosine A2A receptor stimulation on cocaine-seeking behavior in rats. Psychopharmacology (Berl) 206:469–478 (2009).

63. Castane, A., Soria, G., Ledent, C., Maldonado, R. & Valverde, O. Attenuation of nicotine-induced rewarding effects in A2A knockout mice. Neuropharmacology 51:631–640 (2006).

64. Sahraei, H., Motamedi, F., Khoshbaten, A. & Zarrindast, M.R. Adenosine A (2) receptors inhibit morphine self-administration in rats. Eur J Pharmacol 383:107–113 (1999).